Zuellig Pharma Corporation

Zuellig Pharma Corporation, a pharmaceutical preparation manufacturer headquartered in the Philippines, reported a total of approximately 226,142,000 kg CO2e in emissions for the year 2021. This figure encompasses Scope 3 emissions, which amounted to approximately 182,171,000 kg CO2e, with upstream transportation and distribution being a significant contributor. Scope 1 and Scope 2 emissions data were not available for this period.

The company has established robust climate commitments, including a Science Based Targets initiative (SBTi) validated target to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030, using a 2021 baseline. Additionally, Zuellig Pharma aims to reduce absolute Scope 3 GHG emissions by 25% within the same timeframe, focusing on categories such as fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations.

Further commitments include a target to be carbon neutral for its own operations by 2030, with a mid-term goal of a 35% reduction by 2025. Looking towards long-term decarbonisation, Zuellig Pharma is committed to reaching net-zero GHG emissions across its value chain by 2045, with associated long-term reduction targets of 90% for Scope 1 and 2 emissions, and 90% for specific Scope 3 categories by the same year. These targets are aligned with keeping global warming to 1.5°C.

The emissions data and reduction targets for Zuellig Pharma are derived from the organisation itself, with no indication of cascading from a parent or related entity in the provided information.